International Isotopes, Inc. is a U.S.-based company specializing in the production, purification and distribution of radioisotopes and related radiochemicals for medical, industrial and research applications. Through its facilities in Idaho and New Mexico, the company produces isotopes such as iodine-131, rhenium-188 and molybdenum-99—the parent of technetium-99m, which is widely used in diagnostic imaging. International Isotopes also supplies calibration and check sources for radiation detection instruments, including custom shielding and encapsulation services for specialty applications.
In its medical segment, International Isotopes focuses on radiopharmaceutical manufacturing and contract services. The company’s radiochemical expertise supports partners in nuclear medicine by providing high-purity tracers and generator systems for hospitals and imaging centers. On the industrial side, it offers neutron sources—including californium-252—for use in oil exploration, materials analysis and reactor startup testing. International Isotopes also machines and fabricates depleted uranium for radiation shielding, leveraging its licensing under the U.S. Nuclear Regulatory Commission.
Founded in 1995, International Isotopes has pursued the development of a domestic, non-reactor-based molybdenum-99 production facility to reduce reliance on aging research reactors abroad. The company operates under multiple NRC licenses and maintains partnerships with research institutions to advance production technologies. While its core operations are centered in the United States, International Isotopes serves customers globally through export agreements and collaborative ventures in Europe and Asia.
Management is led by President and CEO O. John Ritch, who has overseen expansion of the company’s radiochemical capabilities and regulatory portfolio. Supported by a technical team of radiochemists and engineers, International Isotopes continues to invest in production infrastructure aimed at meeting growing demand for medical isotopes and specialized radiation sources. The company’s strategic focus remains on enhancing supply security for diagnostic and therapeutic nuclear medicine worldwide.
AI Generated. May Contain Errors.
Free INIS Stock Alerts